JOINN Helps Novosta Pharmaceutical to Obtain Implicit Clinical Trial Approval for NSP-1047A

Recently, Novosta Pharmaceutical (Shanghai) Co., Ltd. reached an exhilarating milestone with its Class 1 new chemical drug—the IND application for NSP-1047A tablets successfully received implicit approval for clinical trials. This marks not only a significant milestone for Novosta Pharmaceutical, but also a key step forward in the development of innovative drugs for the treatment of blood disorders.

NSP-1047A tablet is intended for the treatment of relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). AML and MDS are two different hematologic disorders. AML is a malignant proliferation disease of white blood cells, primarily manifested as anemia, bleeding, infection and fever, with a high prognosis risk. If no treatment is given, the survival time of AML patients may be only a few months. Even with treatment, some patients will still relapse, and the prognosis after relapse is worse, with a relatively low 5-year survival rate. MDS is mainly caused by clonal lesions of hematopoietic stem cells, characterized by ineffective hematopoiesis and a high risk of transforming into acute myeloid leukemia. The progression of MDS is slower compared to AML, but some patients will eventually develop AML. Preliminary research has shown that NSP-1047A tablets can effectively intervene in these two diseases and achieve good results.

During the development process of NSP-1047A tablets, JOINN went all out to provide comprehensive support for the project. Our professional team, with extensive experience and sophisticated technology, undertook the **non-clinical efficacy and safety evaluation of the drug, as well as the IND registration application services. From experimental design to data analysis, from toxicity assessment to efficacy verification, every step was meticulously executed to ensure the scientific validity and reliability of the research results.** Our international management team and senior expert team, with a profound understanding of domestic and international regulations and technical standards, have safeguarded the IND application for NSP-1047A tablets, enabling it to successfully navigate the stringent approval process.

The successful approval of the IND application for NSP-1047A tablet is yet another strong testament to the capabilities of JOINN in the field of drug research and development services. We consistently adhere to the philosophy of “being customer-centric and innovation-driven,” dedicating ourselves to providing all-round support for global drug innovation. In the future, we will continue to collaborate with more partners to help develop and launch more innovative drugs, contributing our strengths to the cause of human health.

We believe that in the near future, NSP-1047A tablets will bring new treatment options to patients with relapsed or refractory AML and MDS, giving them renewed hope in life. Let us look forward to NSP-1047A tablets making more breakthroughs in clinical trials and benefiting patients as soon as possible!

昭衍
JOINN